Drug Discovery Services Market
Drug Discovery Services Market by Process, Type, Drug Type, Therapeutic Area, End User & Region | Forecast 2023 to 2033
Spiraling Demand for New Drugs to Boost Drug Discovery Services Market, FMI Analysts Share Growth Insights of 30+ Nations
Drug Discovery Services Market Outlook (2023 to 2033)
The global drug discovery services market size is projected to garner significant growth from 2023 to 2033. According to the research report published by FMI, the global market is anticipated to surpass a valuation of US$ 19.7 billion in 2023. It is likely to hit a valuation of US$ 76.5 billion by 2033. The market is projected to exhibit a captivating CAGR of 14.5% from 2023 to 2033.
New drugs are continuously required to address the various unmet medical needs. Several diseases, including neurodegenerative, cancer, rare genetics, and cardiovascular diseases still lack effective treatment. The emergence of new diseases is spiraling the demand for new drugs. Drug discovery services are expected to increase multifold due to the growing development and discovery of novel drugs.
Drug discovery requires substantial resources and time. As drug discovery becomes complex, the demand for specialized expertise across various scientific disciplines rises. Experts from toxicology, medicinal chemistry, pharmacology, and formulation development usually engage in discovering new drugs. Outsourcing these services can reduce costs and time for research institutions and pharmaceutical companies. The outsourced drug delivery services market provides access to specialized infrastructure and expertise, without any high investments.
Several pharmaceutical, biopharmaceutical, and medical device businesses devote significant resources to developing new medications and technologies. The pharmaceutical sector spends a lot of money on research and development (R&D). The research and development pharmaceutical industry brings high-quality, innovative goods to market. The top pharma companies are enhancing their R&D efficiencies through massive R&D investments to reap long-term benefits.
Initiatives for rare diseases and orphan drug research drive new income streams in the market. However, stringent rules regulating drug research and animal testing may limit market expansion to some extent. Moreover, drug discovery service companies still need to deal with the problem of a scarcity of trained employees.
Attributes |
Details |
Drug Discovery Services Market Share (2022) |
US$ 17.5 billion |
Drug Discovery Services Market Share (2023) |
US$ 19.7 billion |
Drug Discovery Services Market Share (2033) |
US$ 76.5 billion |
Drug Discovery Services Market Share (2023 to 2033) |
14.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Drug Discovery Services Market Historical Analysis (2018 to 2022) Vs. Forecast Outlook (2023 to 2033)
In 2022, the global drug discovery services market size stood at US$ 17.5 billion. The market share is expanding rapidly due to the rising market dynamics for pharmaceuticals. Technical developments are likely to amplify market development. An increase in the adoption of novel methodologies for discovery is observed. Escalating demand for generic medications and an increase in patients expiring, all contribute to rising drug distribution.
The increased research and development in the pharmaceutical industry bolster the market’s growth prospects. The evolution of the healthcare industry combined with the rise in demand for generic medications augments the demand for drug discovery services. The rising geriatric population, and technical developments in drug discovery services, all accelerate the market's growth. Additionally, the growing pharmaceutical sector and a surge in contract development services aid market expansion. Growing manufacturing companies that are promoting drug discovery operations boost sales of drug discovery services.
Other factors that positively influence drug discovery trends include:
- An increase in awareness about chronic diseases
- A surge in the patient pool
- Increasing unmet medical needs
- Increasing funding and reimbursement initiatives
Category-wise Insights
Why do Pharmaceutical Companies Hold a Huge Chunk of the Market Share?
Pharmaceutical companies occupy lion’s share in the global market. The segment accounted for 42% market share in 2022. Pharmaceutical companies rely on market trends and intelligence to devise drug discovery strategies. They collaborate with research institutions and Contract Research Organizations (CROs) to research specific ailments for target audiences. Therefore, the increasing funding from pharmaceutical companies for new drug discoveries bolsters market growth. Moreover, the development and launch of novel drugs give a boost to market growth.
Which Process Segment is Dominant in Drug Discovery Services?
In terms of market share, the Hit-to-lead identification method is the dominant segment. A hit compound is a molecule that exhibits appropriate activity in a screening assay. Researchers use a slew of methods to find the hit molecule. Although, the conventional technique of high-throughput screening is the standard one. Therefore, the lead optimization segment is expected to see increased demand as technology advances and new state-of-the-art facilities arise.
Which Type of Drug Discovery Service Accounts for a Substantial Market Share?
The medicinal chemistry services segment is predicted to increase at a high-double-digit CAGR throughout the forecast period.
The trend of pharmaceutical companies outsourcing research and development services is growing. The expanding drug discovery and development activities and R&D investments are driving the market forward.
During the projection period, the biological services segment in the drug discovery market is expected to increase at a high CAGR.
Which Drug Type in Drug Discovery Services held a Sizable Market Share in 2022?
Small molecules accounted for a huge portion of the drug discovery services market in 2022. The biologics segment is predicted to expand at a remarkable CAGR in the coming years. The growing use of small-molecule medications to treat chronic diseases surges the demand for these drugs.
Small-molecule pharmaceuticals, even though, dominate the global pharmaceutical market, biologics, biosimilars, and large-molecule drugs are gaining market share. Primarily due to the introduction of new biologic-based treatments and rising earnings from current biologics. In addition, biologics and biosimilars necessitate more specialized testing services than small molecules at each level. Therefore, in the next few years, the growing demand for outsourcing these activities to CROs is likely to fuel the expansion of the market.
Which Therapeutic Area Segment Dominated the Global Drug Discovery Market?
Oncology dominated the drug discovery services market in terms of therapeutic areas. It is predicted to continue to do so throughout the forecast period. The segment accounted for an impressive 39.7% market share in 2022. Cancer medicines are in high demand due to increasing cancer cases worldwide. This is likely to make the segment a prominent shareholder in the next years.
Comparative View of the Adjacent Market
Drug Discovery Services Market:
Attributes |
Drug Discovery Services Market |
CAGR (2023 to 2033) |
14.5% |
Market Value (2023) |
US$ 19.7 billion |
Growth Factor |
Surging demand for new drugs to cater to unmet medical needs. |
Future Opportunities |
Discovery and development of novel drugs. |
Market Trends |
Increasing investments and expansion of production capacities. |
Computer-aided Drug Discovery Market:
Attributes |
Computer-aided Drug Discovery Market |
CAGR (2023 to 2033) |
15.2% |
Market Value (2023) |
US$ 5.17 billion |
Growth Factor |
Increasing the cost-efficiency of the drug development process to boost adoption. |
Future Opportunities |
Availability of high-end software and progressive improvement in their efficiency. |
Market Trends |
Strategic partnerships and collaborations for product innovation are a go-to-market move. |
Artificial Intelligence in Drug Discovery Market:
Attributes |
Artificial Intelligence in Drug Discovery Market |
CAGR (2023 to 2033) |
40.2% |
Market Value (2023) |
US$ 1.82 billion |
Growth Factor |
Growing adoption of innovative drug development processes to reduce market times. |
Future Opportunities |
Increasing demand for novel drugs. |
Market Trends |
Expansion of production capabilities. |
There are a few significant factors that limit the market’s growth. The need for a substantial capital investment with low-profit margins hinders market development. A comparatively inadequate healthcare system in middle-income and low-income nations impedes the drug discovery and development process.
The drug discovery services sector continues to remain heavily regulated. This makes the operations complex and removes the layer of adaptability. The years- to decades-long operation can be complicated in the continuous adoption of drug discovery services. There is almost always a chance that medicine may fail to advance to the next stage of research. The lack of predictive accuracy of current animal studies and high drug development costs affect growth prospects. Limited knowledge of underlying illness mechanics, patient diversity, and a lack of endpoints and biomarkers amplify these issues. A high proportion of failed drug trials and legislative obstacles are all constraints that this long research pathway encounters.
Country-wise Insights
Why Does North America Dominate Global Market Share?
North America is a global leader in research and development spending in the pharmaceutical industry. The region accounted for a massive 35.2% market share in 2022. The region is also an outsize market for bulk medications and ready-to-use dosage forms.
The United States accounted for 24.1% market share in 2022. The region’s market works as a free economy, with transparent trading practices and anti-competitive actions restricted. Since biologics is more expensive, the United States has a lot of room for biosimilars. As a result, the United States drug discovery services market is one of the primary competitors for biosimilars.
Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, Darbepoetin Alpha, and other drugs are among the popular players in the United States. As a result of the factors mentioned above, the market is expected to grow rapidly over the forecast period. The progressive increase in regional healthcare spending aids new pharmaceutical technology advancements.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Which Growth Strategies are Likely to be Adopted by Market Players?
The global drug discovery services market is competitive, with Laboratory Corporation of America Holdings (United States), Charles River Laboratories International Inc. (United States), WuXi AppTec (China), and Thermo Fisher Scientific Inc. (United States) collectively accounting for a large portion of the market. The United States-based company, Laboratory Corporation of America Holdings, is a prominent player in the global market.
These key players in the global drug discovery market focus on a broad spectrum of clients. They emphasize incorporating modern and advanced technology-enabled solutions. Increasing investments in joint ventures & partnerships are likely to be prevalent as key strategies. Extensive quality systems and processes contribute to the growth of businesses operating in the market. These companies may use organic and inorganic growth techniques, such as acquisitions and expansions, to tap into new demographics.
Several drugs are pending approval from the United States Food and Drug Administration (FDA).
Anticipated Drug Approvals in 2023:
- In January 2023, Genentech declared that it received a Priority Review and Fast Track designation grant for Glofitamab. The drug is a novel bispecific antibody that engages T-cells of the immune system to treat adult patients with refractory or relapsed LBCL.
- In January 2023, Brexpiprazole, an atypical antipsychotic supplement NDA approved for schizophrenia was put under Priority Review by FDA. Brexpiprazole is a drug developed by H. Lundbeck A/S and Otsuka Pharmaceuticals.
- In January 2023, UCB’s Rozanolixizumab was accepted by the FDA for further Phase III study.
- In December 2022, Harm Reduction Therapeutics announced that FDA accepted and granted Priority for Review to their NDA for RiVive. The product is an over-the-counter naloxone nasal spray.
Key Players in the Market
- Laboratory Corporation of America Holdings
- Charles River Laboratories International Inc.
- Genscript Biotech Corporation
- Thermo Fisher Scientific Inc.
- Pharmaron Beijing Co. Ltd.
- Evotec SE
- Eurofins Scientific SE
- Pharmaceutical Product Development Inc.
- Piramal Enterprise Limited
- Syngene International Limited
Market Segmentation
By Process:
- Target Selection
- Target Validation
- Hit-to-lead identification
- Lead Optimization
- Candidate Validation
By Type:
- Chemistry Services
- Biology Services
By Drug Type:
- Small Molecule Drugs
- Biologics Drugs
By Therapeutic Area:
- Neurology
- Infectious and Immune Systems Diseases
- Digestive System Diseases
- Oncology
- Other Therapeutic Areas
By End User:
- Pharmaceutical & Biotechnology Companies
- Academic Institutes
- Manufacturing
- Other End Users
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- The Middle East & Africa
Frequently Asked Questions
How Big Was the Drug Discovery Services Market in 2022?
The market attained a revenue of US$ 17.5 billion in 2022.
What is the Key Trend Driving Market Growth?
Increasing funding and reimbursement initiatives increases market demand.
Which End-use Industry Holds Lucrative Opportunities?
Pharmaceutical companies offer lucrative opportunities.
Which Process Segment is Dominant in Drug Discovery Services?
The hit-to-lead identification method is the dominant segment.
What is the Current Market Valuation?
The market is estimated to secure a valuation of US$ 19.7 billion in 2023.
Table of Content
1. Executive Summary | Drug Discovery Services Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Process 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Process, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Process, 2023 to 2033 5.3.1. Target Selection 5.3.2. Target Validation 5.3.3. Hit-to-Lead Identification 5.3.4. Lead Optimization 5.3.5. Candidate Validation 5.4. Y-o-Y Growth Trend Analysis By Process, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Process, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 6.3.1. Chemistry Services 6.3.2. Biology Services 6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 7.3.1. Small Molecules Drugs 7.3.2. Biologics Drugs 7.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic Area 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Area, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Area, 2023 to 2033 8.3.1. Neurology 8.3.2. Infectious and Immune System Diseases 8.3.3. Digestive System Diseases 8.3.4. Oncology 8.3.5. Other Therapeutic Area 8.4. Y-o-Y Growth Trend Analysis By Therapeutic Area, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Therapeutic Area, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 9.1. Introduction / Key Findings 9.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 9.3.1. Pharmaceutical & Biotechnology Companies 9.3.2. Academic Institutes 9.3.3. Manufacturing 9.3.4. Other End Users 9.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 9.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 10.1. Introduction 10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. South Asia 10.3.5. East Asia 10.3.6. Oceania 10.3.7. MEA 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. The USA 11.2.1.2. Canada 11.2.2. By Process 11.2.3. By Type 11.2.4. By Drug Type 11.2.5. By Therapeutic Area 11.2.6. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Process 11.3.3. By Type 11.3.4. By Drug Type 11.3.5. By Therapeutic Area 11.3.6. By End User 11.4. Key Takeaways 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Brazil 12.2.1.2. Mexico 12.2.1.3. Rest of Latin America 12.2.2. By Process 12.2.3. By Type 12.2.4. By Drug Type 12.2.5. By Therapeutic Area 12.2.6. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Process 12.3.3. By Type 12.3.4. By Drug Type 12.3.5. By Therapeutic Area 12.3.6. By End User 12.4. Key Takeaways 13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Germany 13.2.1.2. United Kingdom 13.2.1.3. France 13.2.1.4. Spain 13.2.1.5. Italy 13.2.1.6. Rest of Europe 13.2.2. By Process 13.2.3. By Type 13.2.4. By Drug Type 13.2.5. By Therapeutic Area 13.2.6. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Process 13.3.3. By Type 13.3.4. By Drug Type 13.3.5. By Therapeutic Area 13.3.6. By End User 13.4. Key Takeaways 14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Malaysia 14.2.1.3. Singapore 14.2.1.4. Thailand 14.2.1.5. Rest of South Asia 14.2.2. By Process 14.2.3. By Type 14.2.4. By Drug Type 14.2.5. By Therapeutic Area 14.2.6. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Process 14.3.3. By Type 14.3.4. By Drug Type 14.3.5. By Therapeutic Area 14.3.6. By End User 14.4. Key Takeaways 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Process 15.2.3. By Type 15.2.4. By Drug Type 15.2.5. By Therapeutic Area 15.2.6. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Process 15.3.3. By Type 15.3.4. By Drug Type 15.3.5. By Therapeutic Area 15.3.6. By End User 15.4. Key Takeaways 16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. Australia 16.2.1.2. New Zealand 16.2.2. By Process 16.2.3. By Type 16.2.4. By Drug Type 16.2.5. By Therapeutic Area 16.2.6. By End User 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Process 16.3.3. By Type 16.3.4. By Drug Type 16.3.5. By Therapeutic Area 16.3.6. By End User 16.4. Key Takeaways 17. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 17.2.1. By Country 17.2.1.1. GCC Countries 17.2.1.2. South Africa 17.2.1.3. Israel 17.2.1.4. Rest of MEA 17.2.2. By Process 17.2.3. By Type 17.2.4. By Drug Type 17.2.5. By Therapeutic Area 17.2.6. By End User 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.2. By Process 17.3.3. By Type 17.3.4. By Drug Type 17.3.5. By Therapeutic Area 17.3.6. By End User 17.4. Key Takeaways 18. Key Countries Market Analysis 18.1. USA 18.1.1. Pricing Analysis 18.1.2. Market Share Analysis, 2022 18.1.2.1. By Process 18.1.2.2. By Type 18.1.2.3. By Drug Type 18.1.2.4. By Therapeutic Area 18.1.2.5. By End User 18.2. Canada 18.2.1. Pricing Analysis 18.2.2. Market Share Analysis, 2022 18.2.2.1. By Process 18.2.2.2. By Type 18.2.2.3. By Drug Type 18.2.2.4. By Therapeutic Area 18.2.2.5. By End User 18.3. Brazil 18.3.1. Pricing Analysis 18.3.2. Market Share Analysis, 2022 18.3.2.1. By Process 18.3.2.2. By Type 18.3.2.3. By Drug Type 18.3.2.4. By Therapeutic Area 18.3.2.5. By End User 18.4. Mexico 18.4.1. Pricing Analysis 18.4.2. Market Share Analysis, 2022 18.4.2.1. By Process 18.4.2.2. By Type 18.4.2.3. By Drug Type 18.4.2.4. By Therapeutic Area 18.4.2.5. By End User 18.5. Germany 18.5.1. Pricing Analysis 18.5.2. Market Share Analysis, 2022 18.5.2.1. By Process 18.5.2.2. By Type 18.5.2.3. By Drug Type 18.5.2.4. By Therapeutic Area 18.5.2.5. By End User 18.6. United Kingdom 18.6.1. Pricing Analysis 18.6.2. Market Share Analysis, 2022 18.6.2.1. By Process 18.6.2.2. By Type 18.6.2.3. By Drug Type 18.6.2.4. By Therapeutic Area 18.6.2.5. By End User 18.7. France 18.7.1. Pricing Analysis 18.7.2. Market Share Analysis, 2022 18.7.2.1. By Process 18.7.2.2. By Type 18.7.2.3. By Drug Type 18.7.2.4. By Therapeutic Area 18.7.2.5. By End User 18.8. Spain 18.8.1. Pricing Analysis 18.8.2. Market Share Analysis, 2022 18.8.2.1. By Process 18.8.2.2. By Type 18.8.2.3. By Drug Type 18.8.2.4. By Therapeutic Area 18.8.2.5. By End User 18.9. Italy 18.9.1. Pricing Analysis 18.9.2. Market Share Analysis, 2022 18.9.2.1. By Process 18.9.2.2. By Type 18.9.2.3. By Drug Type 18.9.2.4. By Therapeutic Area 18.9.2.5. By End User 18.10. India 18.10.1. Pricing Analysis 18.10.2. Market Share Analysis, 2022 18.10.2.1. By Process 18.10.2.2. By Type 18.10.2.3. By Drug Type 18.10.2.4. By Therapeutic Area 18.10.2.5. By End User 18.11. Malaysia 18.11.1. Pricing Analysis 18.11.2. Market Share Analysis, 2022 18.11.2.1. By Process 18.11.2.2. By Type 18.11.2.3. By Drug Type 18.11.2.4. By Therapeutic Area 18.11.2.5. By End User 18.12. Singapore 18.12.1. Pricing Analysis 18.12.2. Market Share Analysis, 2022 18.12.2.1. By Process 18.12.2.2. By Type 18.12.2.3. By Drug Type 18.12.2.4. By Therapeutic Area 18.12.2.5. By End User 18.13. Thailand 18.13.1. Pricing Analysis 18.13.2. Market Share Analysis, 2022 18.13.2.1. By Process 18.13.2.2. By Type 18.13.2.3. By Drug Type 18.13.2.4. By Therapeutic Area 18.13.2.5. By End User 18.14. China 18.14.1. Pricing Analysis 18.14.2. Market Share Analysis, 2022 18.14.2.1. By Process 18.14.2.2. By Type 18.14.2.3. By Drug Type 18.14.2.4. By Therapeutic Area 18.14.2.5. By End User 18.15. Japan 18.15.1. Pricing Analysis 18.15.2. Market Share Analysis, 2022 18.15.2.1. By Process 18.15.2.2. By Type 18.15.2.3. By Drug Type 18.15.2.4. By Therapeutic Area 18.15.2.5. By End User 18.16. South Korea 18.16.1. Pricing Analysis 18.16.2. Market Share Analysis, 2022 18.16.2.1. By Process 18.16.2.2. By Type 18.16.2.3. By Drug Type 18.16.2.4. By Therapeutic Area 18.16.2.5. By End User 18.17. Australia 18.17.1. Pricing Analysis 18.17.2. Market Share Analysis, 2022 18.17.2.1. By Process 18.17.2.2. By Type 18.17.2.3. By Drug Type 18.17.2.4. By Therapeutic Area 18.17.2.5. By End User 18.18. New Zealand 18.18.1. Pricing Analysis 18.18.2. Market Share Analysis, 2022 18.18.2.1. By Process 18.18.2.2. By Type 18.18.2.3. By Drug Type 18.18.2.4. By Therapeutic Area 18.18.2.5. By End User 18.19. GCC Countries 18.19.1. Pricing Analysis 18.19.2. Market Share Analysis, 2022 18.19.2.1. By Process 18.19.2.2. By Type 18.19.2.3. By Drug Type 18.19.2.4. By Therapeutic Area 18.19.2.5. By End User 18.20. South Africa 18.20.1. Pricing Analysis 18.20.2. Market Share Analysis, 2022 18.20.2.1. By Process 18.20.2.2. By Type 18.20.2.3. By Drug Type 18.20.2.4. By Therapeutic Area 18.20.2.5. By End User 18.21. Israel 18.21.1. Pricing Analysis 18.21.2. Market Share Analysis, 2022 18.21.2.1. By Process 18.21.2.2. By Type 18.21.2.3. By Drug Type 18.21.2.4. By Therapeutic Area 18.21.2.5. By End User 19. Market Structure Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Market Share Analysis of Top Players 19.3.1. By Regional 19.3.2. By Process 19.3.3. By Type 19.3.4. By Drug Type 19.3.5. By Therapeutic Area 19.3.6. By End User 20. Competition Analysis 20.1. Competition Deep Dive 20.1.1. Laboratory Corporation of America Holdings 20.1.1.1. Overview 20.1.1.2. Product Portfolio 20.1.1.3. Profitability by Market Segments 20.1.1.4. Sales Footprint 20.1.1.5. Strategy Overview 20.1.1.5.1. Marketing Strategy 20.1.2. Charles River Laboratories International Inc. 20.1.2.1. Overview 20.1.2.2. Product Portfolio 20.1.2.3. Profitability by Market Segments 20.1.2.4. Sales Footprint 20.1.2.5. Strategy Overview 20.1.2.5.1. Marketing Strategy 20.1.3. Genscript Biotech Corporation 20.1.3.1. Overview 20.1.3.2. Product Portfolio 20.1.3.3. Profitability by Market Segments 20.1.3.4. Sales Footprint 20.1.3.5. Strategy Overview 20.1.3.5.1. Marketing Strategy 20.1.4. Thermo Fisher Scientific Inc. 20.1.4.1. Overview 20.1.4.2. Product Portfolio 20.1.4.3. Profitability by Market Segments 20.1.4.4. Sales Footprint 20.1.4.5. Strategy Overview 20.1.4.5.1. Marketing Strategy 20.1.5. Pharmaron Beijing Co., Ltd. 20.1.5.1. Overview 20.1.5.2. Product Portfolio 20.1.5.3. Profitability by Market Segments 20.1.5.4. Sales Footprint 20.1.5.5. Strategy Overview 20.1.5.5.1. Marketing Strategy 20.1.6. Evotec SE 20.1.6.1. Overview 20.1.6.2. Product Portfolio 20.1.6.3. Profitability by Market Segments 20.1.6.4. Sales Footprint 20.1.6.5. Strategy Overview 20.1.6.5.1. Marketing Strategy 20.1.7. Eurofins Scientific SE 20.1.7.1. Overview 20.1.7.2. Product Portfolio 20.1.7.3. Profitability by Market Segments 20.1.7.4. Sales Footprint 20.1.7.5. Strategy Overview 20.1.7.5.1. Marketing Strategy 20.1.8. Pharmaceutical Product Development, Inc. 20.1.8.1. Overview 20.1.8.2. Product Portfolio 20.1.8.3. Profitability by Market Segments 20.1.8.4. Sales Footprint 20.1.8.5. Strategy Overview 20.1.8.5.1. Marketing Strategy 20.1.9. Piramal Enterprises Limited 20.1.9.1. Overview 20.1.9.2. Product Portfolio 20.1.9.3. Profitability by Market Segments 20.1.9.4. Sales Footprint 20.1.9.5. Strategy Overview 20.1.9.5.1. Marketing Strategy 20.1.10. Syngene International Limited 20.1.10.1. Overview 20.1.10.2. Product Portfolio 20.1.10.3. Profitability by Market Segments 20.1.10.4. Sales Footprint 20.1.10.5. Strategy Overview 20.1.10.5.1. Marketing Strategy 21. Assumptions & Acronyms Used 22. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Process, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 5: Global Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033 Table 6: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Process, 2018 to 2033 Table 9: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 10: North America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 11: North America Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033 Table 12: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 13: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Latin America Market Value (US$ Million) Forecast by Process, 2018 to 2033 Table 15: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 16: Latin America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 17: Latin America Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033 Table 18: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 19: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 20: Europe Market Value (US$ Million) Forecast by Process, 2018 to 2033 Table 21: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 22: Europe Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 23: Europe Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033 Table 24: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 25: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 26: South Asia Market Value (US$ Million) Forecast by Process, 2018 to 2033 Table 27: South Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 28: South Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 29: South Asia Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033 Table 30: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 31: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 32: East Asia Market Value (US$ Million) Forecast by Process, 2018 to 2033 Table 33: East Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 34: East Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 35: East Asia Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033 Table 36: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 37: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 38: Oceania Market Value (US$ Million) Forecast by Process, 2018 to 2033 Table 39: Oceania Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 40: Oceania Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 41: Oceania Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033 Table 42: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 43: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 44: MEA Market Value (US$ Million) Forecast by Process, 2018 to 2033 Table 45: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 46: MEA Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 47: MEA Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033 Table 48: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
List of Charts
Figure 1: Global Market Value (US$ Million) by Process, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Type, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Therapeutic Area, 2023 to 2033 Figure 5: Global Market Value (US$ Million) by End User, 2023 to 2033 Figure 6: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by Process, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by Process, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by Process, 2023 to 2033 Figure 13: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 14: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 15: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 16: Global Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 17: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 18: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 19: Global Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033 Figure 20: Global Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033 Figure 21: Global Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033 Figure 22: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 23: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 24: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 25: Global Market Attractiveness by Process, 2023 to 2033 Figure 26: Global Market Attractiveness by Type, 2023 to 2033 Figure 27: Global Market Attractiveness by Drug Type, 2023 to 2033 Figure 28: Global Market Attractiveness by Therapeutic Area, 2023 to 2033 Figure 29: Global Market Attractiveness by End User, 2023 to 2033 Figure 30: Global Market Attractiveness by Region, 2023 to 2033 Figure 31: North America Market Value (US$ Million) by Process, 2023 to 2033 Figure 32: North America Market Value (US$ Million) by Type, 2023 to 2033 Figure 33: North America Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 34: North America Market Value (US$ Million) by Therapeutic Area, 2023 to 2033 Figure 35: North America Market Value (US$ Million) by End User, 2023 to 2033 Figure 36: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 37: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 38: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 39: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 40: North America Market Value (US$ Million) Analysis by Process, 2018 to 2033 Figure 41: North America Market Value Share (%) and BPS Analysis by Process, 2023 to 2033 Figure 42: North America Market Y-o-Y Growth (%) Projections by Process, 2023 to 2033 Figure 43: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 44: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 45: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 46: North America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 47: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 48: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 49: North America Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033 Figure 50: North America Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033 Figure 51: North America Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033 Figure 52: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 53: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 54: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 55: North America Market Attractiveness by Process, 2023 to 2033 Figure 56: North America Market Attractiveness by Type, 2023 to 2033 Figure 57: North America Market Attractiveness by Drug Type, 2023 to 2033 Figure 58: North America Market Attractiveness by Therapeutic Area, 2023 to 2033 Figure 59: North America Market Attractiveness by End User, 2023 to 2033 Figure 60: North America Market Attractiveness by Country, 2023 to 2033 Figure 61: Latin America Market Value (US$ Million) by Process, 2023 to 2033 Figure 62: Latin America Market Value (US$ Million) by Type, 2023 to 2033 Figure 63: Latin America Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 64: Latin America Market Value (US$ Million) by Therapeutic Area, 2023 to 2033 Figure 65: Latin America Market Value (US$ Million) by End User, 2023 to 2033 Figure 66: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 67: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 68: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 69: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 70: Latin America Market Value (US$ Million) Analysis by Process, 2018 to 2033 Figure 71: Latin America Market Value Share (%) and BPS Analysis by Process, 2023 to 2033 Figure 72: Latin America Market Y-o-Y Growth (%) Projections by Process, 2023 to 2033 Figure 73: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 74: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 75: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 76: Latin America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 77: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 78: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 79: Latin America Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033 Figure 80: Latin America Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033 Figure 81: Latin America Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033 Figure 82: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 83: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 84: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 85: Latin America Market Attractiveness by Process, 2023 to 2033 Figure 86: Latin America Market Attractiveness by Type, 2023 to 2033 Figure 87: Latin America Market Attractiveness by Drug Type, 2023 to 2033 Figure 88: Latin America Market Attractiveness by Therapeutic Area, 2023 to 2033 Figure 89: Latin America Market Attractiveness by End User, 2023 to 2033 Figure 90: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 91: Europe Market Value (US$ Million) by Process, 2023 to 2033 Figure 92: Europe Market Value (US$ Million) by Type, 2023 to 2033 Figure 93: Europe Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 94: Europe Market Value (US$ Million) by Therapeutic Area, 2023 to 2033 Figure 95: Europe Market Value (US$ Million) by End User, 2023 to 2033 Figure 96: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 97: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 98: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 99: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 100: Europe Market Value (US$ Million) Analysis by Process, 2018 to 2033 Figure 101: Europe Market Value Share (%) and BPS Analysis by Process, 2023 to 2033 Figure 102: Europe Market Y-o-Y Growth (%) Projections by Process, 2023 to 2033 Figure 103: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 104: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 105: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 106: Europe Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 107: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 108: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 109: Europe Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033 Figure 110: Europe Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033 Figure 111: Europe Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033 Figure 112: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 113: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 114: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 115: Europe Market Attractiveness by Process, 2023 to 2033 Figure 116: Europe Market Attractiveness by Type, 2023 to 2033 Figure 117: Europe Market Attractiveness by Drug Type, 2023 to 2033 Figure 118: Europe Market Attractiveness by Therapeutic Area, 2023 to 2033 Figure 119: Europe Market Attractiveness by End User, 2023 to 2033 Figure 120: Europe Market Attractiveness by Country, 2023 to 2033 Figure 121: South Asia Market Value (US$ Million) by Process, 2023 to 2033 Figure 122: South Asia Market Value (US$ Million) by Type, 2023 to 2033 Figure 123: South Asia Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 124: South Asia Market Value (US$ Million) by Therapeutic Area, 2023 to 2033 Figure 125: South Asia Market Value (US$ Million) by End User, 2023 to 2033 Figure 126: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 127: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 128: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 129: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 130: South Asia Market Value (US$ Million) Analysis by Process, 2018 to 2033 Figure 131: South Asia Market Value Share (%) and BPS Analysis by Process, 2023 to 2033 Figure 132: South Asia Market Y-o-Y Growth (%) Projections by Process, 2023 to 2033 Figure 133: South Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 134: South Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 135: South Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 136: South Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 137: South Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 138: South Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 139: South Asia Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033 Figure 140: South Asia Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033 Figure 141: South Asia Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033 Figure 142: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 143: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 144: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 145: South Asia Market Attractiveness by Process, 2023 to 2033 Figure 146: South Asia Market Attractiveness by Type, 2023 to 2033 Figure 147: South Asia Market Attractiveness by Drug Type, 2023 to 2033 Figure 148: South Asia Market Attractiveness by Therapeutic Area, 2023 to 2033 Figure 149: South Asia Market Attractiveness by End User, 2023 to 2033 Figure 150: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 151: East Asia Market Value (US$ Million) by Process, 2023 to 2033 Figure 152: East Asia Market Value (US$ Million) by Type, 2023 to 2033 Figure 153: East Asia Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 154: East Asia Market Value (US$ Million) by Therapeutic Area, 2023 to 2033 Figure 155: East Asia Market Value (US$ Million) by End User, 2023 to 2033 Figure 156: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 157: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 158: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 159: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 160: East Asia Market Value (US$ Million) Analysis by Process, 2018 to 2033 Figure 161: East Asia Market Value Share (%) and BPS Analysis by Process, 2023 to 2033 Figure 162: East Asia Market Y-o-Y Growth (%) Projections by Process, 2023 to 2033 Figure 163: East Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 164: East Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 165: East Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 166: East Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 167: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 168: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 169: East Asia Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033 Figure 170: East Asia Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033 Figure 171: East Asia Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033 Figure 172: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 173: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 174: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 175: East Asia Market Attractiveness by Process, 2023 to 2033 Figure 176: East Asia Market Attractiveness by Type, 2023 to 2033 Figure 177: East Asia Market Attractiveness by Drug Type, 2023 to 2033 Figure 178: East Asia Market Attractiveness by Therapeutic Area, 2023 to 2033 Figure 179: East Asia Market Attractiveness by End User, 2023 to 2033 Figure 180: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 181: Oceania Market Value (US$ Million) by Process, 2023 to 2033 Figure 182: Oceania Market Value (US$ Million) by Type, 2023 to 2033 Figure 183: Oceania Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 184: Oceania Market Value (US$ Million) by Therapeutic Area, 2023 to 2033 Figure 185: Oceania Market Value (US$ Million) by End User, 2023 to 2033 Figure 186: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 187: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 188: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 189: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 190: Oceania Market Value (US$ Million) Analysis by Process, 2018 to 2033 Figure 191: Oceania Market Value Share (%) and BPS Analysis by Process, 2023 to 2033 Figure 192: Oceania Market Y-o-Y Growth (%) Projections by Process, 2023 to 2033 Figure 193: Oceania Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 194: Oceania Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 195: Oceania Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 196: Oceania Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 197: Oceania Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 198: Oceania Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 199: Oceania Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033 Figure 200: Oceania Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033 Figure 201: Oceania Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033 Figure 202: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 203: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 204: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 205: Oceania Market Attractiveness by Process, 2023 to 2033 Figure 206: Oceania Market Attractiveness by Type, 2023 to 2033 Figure 207: Oceania Market Attractiveness by Drug Type, 2023 to 2033 Figure 208: Oceania Market Attractiveness by Therapeutic Area, 2023 to 2033 Figure 209: Oceania Market Attractiveness by End User, 2023 to 2033 Figure 210: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 211: MEA Market Value (US$ Million) by Process, 2023 to 2033 Figure 212: MEA Market Value (US$ Million) by Type, 2023 to 2033 Figure 213: MEA Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 214: MEA Market Value (US$ Million) by Therapeutic Area, 2023 to 2033 Figure 215: MEA Market Value (US$ Million) by End User, 2023 to 2033 Figure 216: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 217: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 218: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 219: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 220: MEA Market Value (US$ Million) Analysis by Process, 2018 to 2033 Figure 221: MEA Market Value Share (%) and BPS Analysis by Process, 2023 to 2033 Figure 222: MEA Market Y-o-Y Growth (%) Projections by Process, 2023 to 2033 Figure 223: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 224: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 225: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 226: MEA Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 227: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 228: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 229: MEA Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033 Figure 230: MEA Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033 Figure 231: MEA Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033 Figure 232: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 233: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 234: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 235: MEA Market Attractiveness by Process, 2023 to 2033 Figure 236: MEA Market Attractiveness by Type, 2023 to 2033 Figure 237: MEA Market Attractiveness by Drug Type, 2023 to 2033 Figure 238: MEA Market Attractiveness by Therapeutic Area, 2023 to 2033 Figure 239: MEA Market Attractiveness by End User, 2023 to 2033 Figure 240: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports